Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Chris Lange | Nov 13, 2017 at 1:30 PM EST

Why Argus Is Taking a Step Back on Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded…

Jon C. Ogg | Nov 13, 2017 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

The top analyst upgrades, downgrades and other research calls from Monday include Best Buy, Equifax, Gilead Sciences, MongoDB, NVIDIA, Rio…

Chris Lange | Nov 10, 2017 at 10:40 AM EST

Short Sellers Grow More Selective on Major Biotechs

The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech…

Chris Lange | Oct 28, 2017 at 8:40 AM EDT

Despite Poor Earnings Reaction, Analysts Still See Upside for Gilead

Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been…

Jon C. Ogg | Oct 26, 2017 at 4:18 PM EDT

Gilead Earnings Bring Mixed Results

Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The…

Chris Lange | Oct 25, 2017 at 10:40 AM EDT

Short Sellers Chase Biotechs Higher

The October 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 22, 2017 at 10:45 AM EDT

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.

Jon C. Ogg | Oct 19, 2017 at 12:15 PM EDT

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some…

Jon C. Ogg | Oct 12, 2017 at 2:05 PM EDT

Are Analysts Secretly Calling Gilead a Screaming Buy?

Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past…

Chris Lange | Oct 11, 2017 at 11:35 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech…

Jon C. Ogg | Oct 11, 2017 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa…

Jon C. Ogg | Oct 5, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and…

Jon C. Ogg | Oct 4, 2017 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Freeport-McMoran, Gilead Sciences, FuelCell, Oracle, Take-Two Interactive, Tesla…

Chris Lange | Sep 28, 2017 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a relatively mixed day for the U.S. broad markets. Although all the major averages started off negative a…

Chris Lange | Sep 27, 2017 at 10:25 AM EDT

Short Sellers Hike Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest in all the selected…

1 … 18 19 20 21 22 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Argus Is Taking a Step Back on Gilead Sciences

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

Short Sellers Grow More Selective on Major Biotechs

Despite Poor Earnings Reaction, Analysts Still See Upside for Gilead

Gilead Earnings Bring Mixed Results

Short Sellers Chase Biotechs Higher

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Are Analysts Secretly Calling Gilead a Screaming Buy?

Short Sellers Grow More Selective on Major Biotechs

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Hike Bets in Major Biotechs

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

No, Your Teacher Pension Isn’t Enough, and the $49,000 Loophole Buried in Your Own Benefits Packet Could Save Your Retirement

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

Gilead Sciences : GILD

All Gilead Sciences Articles

Why Argus Is Taking a Step Back on Gilead Sciences

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

Short Sellers Grow More Selective on Major Biotechs

Despite Poor Earnings Reaction, Analysts Still See Upside for Gilead

Gilead Earnings Bring Mixed Results

Short Sellers Chase Biotechs Higher

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Are Analysts Secretly Calling Gilead a Screaming Buy?

Short Sellers Grow More Selective on Major Biotechs

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Hike Bets in Major Biotechs

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

No, Your Teacher Pension Isn’t Enough, and the $49,000 Loophole Buried in Your Own Benefits Packet Could Save Your Retirement

Featured Reads

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check